StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research note published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
NASDAQ BLPH opened at $0.01 on Friday. Bellerophon Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.02. The company has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The company has a fifty day moving average of $0.03 and a 200 day moving average of $0.04.
Bellerophon Therapeutics Dividend Announcement
The business also recently announced a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were paid a $0.019 dividend. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 117.8%.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- NYSE Stocks Give Investors a Variety of Quality Options
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
